In an exclusive interview, Doblin discusses MAPS’s goal to raise $150 over the next three years, and their $70 million investment fund with Vine Ventures to help meet that funding goal.
Ketamine clinics, which look like everything from a med spa to an art gallery, are cropping up all over the country, including progressive and wealthy cities such as New York.
BMed, a new Spanish nonprofit that will focus on training psychedelic facilitators and educating the general public, stresses the need for community building in the burgeoning psychedelic revival.
The mental health company Novamind is at the forefront of providing contract research services with clinical expertise in psychedelic-assisted therapies.
A growing number of psychedelic companies are launching programs to give back to the indigenous tribes whose traditional uses of psychedelics have been critical in shaping contemporary approaches to these medicines.
Therapies are being developed for conditions ranging from Treatment Resistant Depression to strokes to addiction.
Parallels between business and regulation strategies in the two sectors point to examples of what psychedelics companies should and should not do.
A new wave of companies are assisting counselors with medicine, records, music and training.
Miraculix’s kit, the first to offer quantitative rapid results within 10 to 30 minutes, is a significant innovation considering many of the substances people desire to test are illegal.
Cybin and Greenbrook announce partnership to roll out clinic expansion and development of psychedelic therapies.